Longevity Startups

BioRestorative Therapies develops cell- and tissue-based therapeutic products, primarily using adult stem cells, targeting conditions such as degenerative disc disease and metabolic disorders. It also runs a BioCosmeceutical platform applying secretome-based biologics to aesthetic medicine, and is a publicly traded company (NASDAQ:BRTX).

0 investors

BioVie is a clinical-stage biopharmaceutical company developing bezisterim, a molecule studied for neurodegenerative and inflammatory conditions including Alzheimer's disease, Parkinson's disease, and Long COVID, alongside work on liver disease complications such as ascites. It also researches longevity and epigenetic mechanisms like DNA methylation.

0 investors

Bioxytran is a clinical-stage pharmaceutical company developing carbohydrate-based drug platforms in glycovirology, hypoxia, and degenerative diseases, using galectin inhibitors to block viral replication and oxygen-carrying treatments for conditions such as stroke, wounds, and brain damage. Its therapies target viruses, hypoxic conditions, necrosis, and degenerative diseases.

0 investors

BodyBio is a third-generation family business that develops and manufactures science-backed dietary supplements and vitamins, including phosphatidylcholine (PC), butyrate, and detox products, aimed at cellular health and wellness. Products are made at the company's in-house facility with third-party testing.

0 investors

bQuest connects financial advisors with a vetted network of aging care, end-of-life, and after-loss specialists to help clients and families navigate care crises. The platform uses AI-powered guidance to support wealth management firms in serving aging populations.

0 investors

Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy. The company translates research on the melanocortin system into therapeutic candidates for patients with MC4R pathway-driven obesity in the US.

0 investors

32 Biosciences develops gastrointestinal therapeutics that target gut microbial and host-microbe biology, with a lead candidate aimed at preventing surgical site infections in high-risk GI surgery. It uses a functional metabolomics discovery platform to support biomarkers, patient stratification, and drug discovery.

0 investors

Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.

0 investors

Edenbridge Health develops and operates PACE (Program for All-Inclusive Care for the Elderly) centers that provide comprehensive, community-based medical and social care for frail, low-income older adults. The company runs centers in markets including Baltimore and Washington, D.C., and partners with housing providers to help elders age in place.

0 investors

FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.

0 investors

Foment Bio develops non-viral, off-the-shelf plasmid gene therapy constructs that trigger in vivo production of regenerative exosomes to restore tissue microvasculature, resolve inflammation, and prevent cell death. The therapy targets age-related and cardiometabolic chronic diseases including heart failure, chronic kidney disease, erectile dysfunction, and wound healing, and has advanced into FDA clinical trials.

0 investors

Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates. Its lead programs include a topically applied small-molecule combination to reverse age- and weight-loss-associated skin atrophy and a small-molecule modulator to preserve lean tissue and muscle mass in sarcopenia and GLP agonist-induced atrophy.

0 investors

Generian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.

0 investors

Geviti offers a subscription-based proactive health and longevity program that tests 100+ blood biomarkers twice a year and pairs members with a dedicated care team, medical providers, and an AI assistant to build personalized supplement and health protocols. It serves individuals seeking preventive, data-driven health optimization beyond a standard annual physical.

0 investors

Gracewell operates two boutique residential care homes offering assisted living for seniors, with a focus on small-scale, home-like settings and personalized wellness support. The homes are designed as an alternative to large facilities, emphasizing intimate care relationships for residents and their families.

0 investors

Human Continuum Inc. is a healthcare company focused on sports medicine, regenerative medicine, and musculoskeletal health services led by experienced clinical physicians and researchers.

0 investors

iBio is a biopharmaceutical company with leadership experienced in drug discovery, development, and clinical operations across multiple therapeutic areas. The company appears to focus on innovative therapeutics and biologics development.

0 investors

Immunaeon provides cellular banking and cryopreservation services, helping individuals preserve their healthiest cells for potential future medical use. The company serves patients seeking to maintain medical options through cell preservation, with an emphasis on clear communication and privacy protection.

0 investors

ImmunoMet Therapeutics is a clinical-stage oncology drug developer working to advance lixumistat, a compound targeting oxidative phosphorylation in cancer to address resistance to existing treatments. Founded in 2015 as a spin-off from HanAll Biopharma, the company runs its clinical programs with specialist CROs and partners, including trials at MD Anderson Cancer Center.

0 investors

InGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.

0 investors

Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.

0 investors

The page presents team members affiliated with Cambrian Bio, describing roles in R&D project management, business operations, and medicinal chemistry consulting within drug discovery and development. The individuals have backgrounds in developing medicines and small-molecule therapeutics across pharma and biotech.

0 investors

JangoBio is a biotechnology company developing regenerative stem cell therapies aimed at aging and age-related diseases by restoring sex hormone balance. It builds cell-based organoids designed to regenerate or replace gonadal tissues lost during aging to increase hormone production and longevity.

0 investors

Jupiter Biomedical Research is a drug development company with patents for two therapeutic candidates: JBR-102, an oral treatment for glioblastoma multiforme and other brain tumors, and JBR-201, an antiviral treatment for measles virus infections and related neurological diseases. The company is pursuing regulatory approval from Health Canada and the FDA for its lead cancer candidate while advancing preclinical development of its antiviral program.

0 investors